2022. COMBO-MESA

Randomized controlled, investigator-blinded trial, Patients with ASUC received Corticosteroids or corticosteroid + mesalazine 4 gr per day by stratified randomisation depending on mesalamine use before admission.

<u>Primary endpoint:</u> Response to treatment by day 7 by a drop>3 points in the Lichtiger score and an absolute score <10 without the need of rescue medication or colectomy.


## Results:

- Response day 7: Corticosteroids+5ASA 72.6% vs corticosteroids alone 76.3%, p=0.6
- No difference between groups in duration of hospitalization, CRP normalization rate or colectomy up to 90 days.
- The need for biologics among patients on combination was lower by day 30 and day 90 p=0.07

## Conclusions:

Combination of mesalazine with corticosteroids did not benefit hospitalized patients with ASUC more than corticosteroids alone. An exploratory signal for a reduced need for biologics at 90 days in the mesalazine group merits further evaluation

## Corticosteroids and mesalazine versus corticosteroids for acute severe Ulcerative colitis: A randomized control trial



H